GlobalData on MSN19h
Takeda announces appointment of Julie Kim as CEO
Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and ...
Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEO
The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...
Takeda Pharmaceutical Co.: Hold Rating Amid Mixed Q3 Results, Upward Guidance Revision, and Strategic Moves
Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...
FierceBiotech23h
Takeda axes failed epilepsy asset after FDA weighs in on data package
Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...
ThePrint5h
Celebrating the Legacy of Excellence and Innovation, Zydus Takeda Healthcare marks 25 years of manufacturing operations in India
India], January 31: Zydus Takeda Healthcare Private Limited (ZTHPL), a joint venture company set up by Zydus Lifesciences ...
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended ...
Takeda Pharmaceutical (TAK) Projected to Post Quarterly Earnings on Thursday
Takeda Pharmaceutical (NYSE:TAK – Get Free Report) is projected to announce its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of ...
FierceBiotech3d
Takeda regains home rights to phase 3-stage depression drug from Neurocrine
Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...